OncoMatch/Clinical Trials/NCT06589089
Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy
Is NCT06589089 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies autologous hematopoietic stem cell for diffuse large b cell lymphoma.
Treatment: autologous hematopoietic stem cell — This is a prospective, single-arm, open study to observe the efficacy and safety of the CART-SCB regimen (Clinical Regimen for the Prospective Study of Autologous Hematopoietic Stem Cell Boost for the Improvement of Bone Marrow Suppression in Patients with High-Risk Immunohematologic Toxicity Lymphoma After Chimeric Antigen Receptor T (CAR-T)-Cell Immunotherapy Therapy) . After the patient has completed CAR-T therapy, if the patient has unrelieved hematologic toxicity, consider infusing a reserve of stem cells; if myelosuppression has not been significantly relieved, stem cell infusion can be performed again.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Prior therapy
Must have received: CAR-T cell therapy
Prior CAR-T cell immunotherapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
History of allogeneic hematopoietic stem cell transplantation
Lab requirements
Blood counts
Myelosuppression as determined by the investigator has occurred after CAR-T therapy
Cardiac function
Severe cardiovascular disease: grade II or greater myocardial ischemia or myocardial infarction, poorly controlled arrhythmias; grade III-IV cardiac insufficiency according to NYHA criteria, or cardiac ultrasound suggestive of a left ventricular ejection fraction (LVEF) <50%
Adequate organ function; Myelosuppression as determined by the investigator has occurred after CAR-T therapy; Suffering from severe cardiovascular disease: grade II or greater myocardial ischemia or myocardial infarction, poorly controlled arrhythmias; grade III-IV cardiac insufficiency according to New York Heart Association (NYHA) criteria, or cardiac ultrasound suggestive of a left ventricular ejection fraction (LVEF) <50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify